P10.04 Immunotherapy-Treated Non-Small Cell Lung Cancer Patients With Sensitizing Gene Alterations: A Real World Survival Analysis
Leila Khaddour(Henry Ford Health System), Igor I. Rybkin(Henry Ford Hospital), Shirish M. Gadgeel(Chinese University of Hong Kong), Eyob Tadesse, Connor Sweetnam, Jonathan Treisman(Ascension), Michael A. Thompson(The University of Melbourne), Monika A. Izano(Syndicat des Sélectionneurs Avicoles et Aquacoles Français), Andrew Stafford, Anna B. Berry, Cheng Zhang, Douglas J. Reding(Ascension), F. Ali(Henry Ford Health System), F Wolf, Tamara Brown
Cited by 1
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
|Controlled Clinical Trials|2000|1k